BR0317780A - Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas - Google Patents
Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidasInfo
- Publication number
- BR0317780A BR0317780A BR0317780-7A BR0317780A BR0317780A BR 0317780 A BR0317780 A BR 0317780A BR 0317780 A BR0317780 A BR 0317780A BR 0317780 A BR0317780 A BR 0317780A
- Authority
- BR
- Brazil
- Prior art keywords
- treating hemorrhoids
- thrombolytically
- proteins
- rectal administration
- suppository formulation
- Prior art date
Links
- 239000000829 suppository Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 208000014617 hemorrhoid Diseases 0.000 title 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMULAçãO NA FORMA DE SUPOSITóRIO PARA A ADMINISTRAçãO RETAL, MéTODO PARA O TRATAMENTO DE HEMORRóIDAS, E USO DE PEPTìDEOS E PROTEìNAS COM AçãO TROMBOLìTICA PARA O TRATAMENTO DE HEMORRóIDAS". Formulações farmacêuticas em forma de supositórios que contém agentes com ação trombolítica capazes de penetrar na mucosa retal para o tratamento da enfermidade hemorroidal aguda e/ou de origem trombótica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20020336A CU23203A1 (es) | 2002-12-27 | 2002-12-27 | Formulaciones que contienen agentes de accion trombolitica para su administracion por via rectal |
| PCT/CU2003/000020 WO2004058219A1 (es) | 2002-12-27 | 2003-12-22 | Formulaciones para administrar por vía rectal agentes con acción trombolítica |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0317780A true BR0317780A (pt) | 2005-11-22 |
| BRPI0317780B1 BRPI0317780B1 (pt) | 2018-11-21 |
| BRPI0317780B8 BRPI0317780B8 (pt) | 2021-05-25 |
Family
ID=40091670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0317780A BRPI0317780B8 (pt) | 2002-12-27 | 2003-12-22 | uso de supositório de estreptoquinase com ação trombolítica |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10213379B2 (pt) |
| EP (1) | EP1576951B1 (pt) |
| JP (1) | JP2006512374A (pt) |
| KR (1) | KR100804013B1 (pt) |
| CN (1) | CN100335128C (pt) |
| AR (1) | AR042646A1 (pt) |
| AT (1) | ATE409460T1 (pt) |
| AU (1) | AU2003291916B2 (pt) |
| BR (1) | BRPI0317780B8 (pt) |
| CA (1) | CA2527572C (pt) |
| CU (1) | CU23203A1 (pt) |
| DE (1) | DE60323874D1 (pt) |
| DK (1) | DK1576951T3 (pt) |
| ES (1) | ES2315537T3 (pt) |
| MX (1) | MXPA05007006A (pt) |
| MY (1) | MY142241A (pt) |
| PT (1) | PT1576951E (pt) |
| WO (1) | WO2004058219A1 (pt) |
| ZA (1) | ZA200505399B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660429B (zh) * | 2005-01-10 | 2011-09-07 | 王振军 | 基质金属蛋白酶（mmp）抑制剂用于治疗痔的新用途 |
| CN100364610C (zh) * | 2005-12-12 | 2008-01-30 | 北京大学 | 提高蚓激酶口服吸收生物利用度的方法 |
| CN102091326B (zh) * | 2009-12-15 | 2013-04-03 | 上海凯茂生物医药有限公司 | 治疗因肛门皮下的静脉丛发生扩大或曲张所引发的痔类疾病的经皮给药制剂及制备方法 |
| CN102552916B (zh) * | 2010-12-09 | 2014-04-23 | 上海凯茂生物医药有限公司 | 水杨酸钠的新用途 |
| EP3115037B1 (de) * | 2015-07-08 | 2018-08-15 | Dr. Falk Pharma Gmbh | Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3804600A1 (de) * | 1988-02-13 | 1989-08-24 | Basf Ag | Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz |
| GB8808810D0 (en) * | 1988-04-14 | 1988-05-18 | Biopharm Clinical Research Ltd | Heparin-containing formulations |
| US5098707A (en) * | 1989-07-31 | 1992-03-24 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| US5885967A (en) | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
| US5720962A (en) * | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
| US5837688A (en) * | 1996-11-27 | 1998-11-17 | Gelfand; Mathew I. | Use of thrombolytic reagents for prevention of vascular disease |
| EP1021195A1 (en) | 1997-10-07 | 2000-07-26 | The Regents Of The University Of California | Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| AU7965000A (en) * | 1999-09-27 | 2001-04-30 | Jun-Suk Oh | Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same |
-
2002
- 2002-12-27 CU CU20020336A patent/CU23203A1/es unknown
-
2003
- 2003-12-22 JP JP2004562479A patent/JP2006512374A/ja not_active Ceased
- 2003-12-22 DK DK03767381T patent/DK1576951T3/da active
- 2003-12-22 MX MXPA05007006A patent/MXPA05007006A/es active IP Right Grant
- 2003-12-22 AT AT03767381T patent/ATE409460T1/de active
- 2003-12-22 KR KR1020057011945A patent/KR100804013B1/ko active IP Right Grant
- 2003-12-22 BR BRPI0317780A patent/BRPI0317780B8/pt active IP Right Grant
- 2003-12-22 PT PT03767381T patent/PT1576951E/pt unknown
- 2003-12-22 CN CNB2003801088471A patent/CN100335128C/zh not_active Expired - Lifetime
- 2003-12-22 US US10/540,296 patent/US10213379B2/en active Active
- 2003-12-22 EP EP03767381A patent/EP1576951B1/en not_active Expired - Lifetime
- 2003-12-22 DE DE60323874T patent/DE60323874D1/de not_active Expired - Lifetime
- 2003-12-22 AR ARP030104771A patent/AR042646A1/es not_active Application Discontinuation
- 2003-12-22 AU AU2003291916A patent/AU2003291916B2/en not_active Ceased
- 2003-12-22 ES ES03767381T patent/ES2315537T3/es not_active Expired - Lifetime
- 2003-12-22 CA CA2527572A patent/CA2527572C/en not_active Expired - Lifetime
- 2003-12-22 WO PCT/CU2003/000020 patent/WO2004058219A1/es active IP Right Grant
- 2003-12-26 MY MYPI20035014A patent/MY142241A/en unknown
-
2005
- 2005-07-04 ZA ZA200505399A patent/ZA200505399B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60323874D1 (de) | 2008-11-13 |
| ES2315537T3 (es) | 2009-04-01 |
| CN1738602A (zh) | 2006-02-22 |
| US10213379B2 (en) | 2019-02-26 |
| JP2006512374A (ja) | 2006-04-13 |
| BRPI0317780B8 (pt) | 2021-05-25 |
| AU2003291916A1 (en) | 2004-07-22 |
| KR20050088219A (ko) | 2005-09-02 |
| EP1576951B1 (en) | 2008-10-01 |
| MXPA05007006A (es) | 2005-08-18 |
| AU2003291916B2 (en) | 2007-03-08 |
| KR100804013B1 (ko) | 2008-02-18 |
| CN100335128C (zh) | 2007-09-05 |
| AR042646A1 (es) | 2005-06-29 |
| PT1576951E (pt) | 2009-01-09 |
| DK1576951T3 (da) | 2009-02-02 |
| ATE409460T1 (de) | 2008-10-15 |
| CA2527572A1 (en) | 2004-07-15 |
| CA2527572C (en) | 2010-03-30 |
| ZA200505399B (en) | 2006-04-26 |
| EP1576951A1 (en) | 2005-09-21 |
| CU23203A1 (es) | 2007-05-18 |
| MY142241A (en) | 2010-11-15 |
| BRPI0317780B1 (pt) | 2018-11-21 |
| WO2004058219A1 (es) | 2004-07-15 |
| US20070166298A1 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074774L (no) | Blandinger omfattende DNA-odeleggende midler og P53 | |
| BR9806747A (pt) | Sistema terapêutico transdérmico. | |
| BR9812965A (pt) | Métodos para tratamento de estados hipercoaguláveis ou deficiência de proteìna c adquirida | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| BR0207760A (pt) | Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| MX9203278A (es) | Pastilla de liberacion sustentada que comprende loratadina, ibuprofen y pseudoefedrina. | |
| BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
| BR9916694A (pt) | Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal | |
| BR0113400A (pt) | Método para seleção de peptìdeo | |
| SE9404196D0 (sv) | New antithrombotic formulation | |
| AR025001A1 (es) | Formulacion de sal comun y moxifloxacina | |
| BRPI0208411B8 (pt) | composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto | |
| BR9912773A (pt) | Processo e aparelho para o tratamento tópico de tecido doente e processo para o tratamento de doenças em vasos do sistema circulatório | |
| BR9807523A (pt) | Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids. | |
| RS49599B (sr) | Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija | |
| BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
| BR0209206A (pt) | Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo | |
| BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
| BR0101486A (pt) | Composições farmacêuticas de uso tópico, aplicadas no tratamento de lesões de pele e/ou mucosas; uso das composições no tratamento de lesões de pele e/ou mucosas e uso de compostos no tratamento de lesões de pele e/ou mucosas | |
| BR0317780A (pt) | Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas | |
| BR0204573A (pt) | Composição para redução da irritação cutânea enzimática | |
| BR9908716A (pt) | Tratamento de disfunção sexual em certos grupos de pacientes | |
| DE50113974D1 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
| BR0213410A (pt) | Usos farmacêuticos de bisfosfonatos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/02 , A61K 38/49 Ipc: A61K 9/02 (2006.01), A61K 38/49 (2006.01), A61K 38 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |